Cinacalcet, a calcium-sensing receptor (CaSR) allosteric agonist is used to control hyperparathyroidism and hypercalcemia (Zitt et al., 2011; Chertow et al., 2012; Leere et al., 2017) in a number of clinical scenarios. Here, CASR is linked to hyperparathyroidism.